Adia Med Receives IRB Approval for Autism Clinical Trial Combining Stem Cells with Glutathione
核心洞察
Adia Nutrition Inc. (搜索) announced that BeyondBound (搜索) IRB has approved their clinical study protocol investigating autism spectrum disorder (搜索) treatments in children ages 3-12.
The study will enroll 100 participants to compare the therapeutic benefits of combining glutathione with umbilical cord blood-derived stem cells (搜索) versus glutathione alone.
Patient recruitment is expected to begin in January 2026, with the study serving as a foundational model for additional clinical trials targeting various conditions.
Adia Nutrition Inc. (搜索) has received Institutional Review Board (IRB) approval from BeyondBound (搜索) for a clinical study investigating novel treatment approaches for Autism Spectrum Disorder (搜索) (ASD) in pediatric patients. The approval represents a significant milestone for the company's regenerative medicine subsidiary, Adia Med (搜索), as it advances into clinical research.
Study Design and Objectives
The approved study, titled "Adia Med (搜索) of Winter Park LLC Autism Spectrum Disorder (搜索) Research Study," will enroll 100 children between the ages of 3 and 12 years. The research aims to investigate whether combining glutathione with umbilical cord blood-derived stem cells (搜索) provides superior therapeutic benefits compared to glutathione treatment alone.
The study's primary focus centers on measuring potential improvements across several core areas affected by ASD, including social interaction, communication abilities, behavioral patterns, and overall quality of life. These outcome measures address fundamental challenges faced by individuals with autism spectrum disorder (搜索) and their families.
Clinical Development Timeline
Patient recruitment is scheduled to commence in January 2026, with Adia Nutrition committing to provide regular updates on enrollment progress and study advancement. The company has submitted study details to ClinicalTrials.gov, which are currently undergoing final review before becoming publicly accessible.
"This approval from BeyondBound (搜索) is a key milestone in advancing potential new options for individuals and families affected by autism," said Larry Powalisz, CEO of Adia Nutrition Inc. (搜索) "We are truly grateful to our Medical Director, Dr. Evan Thomas MD PhD, for leading this important study with exceptional diligence and expertise."
Strategic Research Platform
The autism study will serve as the foundational model for Adia Med (搜索)'s expanded clinical research program planned for 2026. The company intends to conduct additional studies targeting various other medical conditions, with Adia Med acting as sponsor for research conducted at partner clinics across multiple therapeutic indications.
This clinical development strategy aligns with the company's broader regenerative medicine portfolio, which includes stem cell therapies, platelet-rich plasma (PRP) treatments, therapeutic plasma exchange (TPE), and autologous hematopoietic stem cell transplantation (aHSCT).
Regulatory and Intellectual Property Developments
The clinical trial approval follows Adia Nutrition's recent filing of a provisional patent application with the United States Patent and Trademark Office (USPTO) for a novel medical protocol designed to enhance regenerative outcomes. The proprietary protocol leverages unique procedural and biological mechanisms previously unexplored in clinical practice.
"Securing this provisional patent marks a pivotal step in protecting our intellectual property while accelerating development of next-generation health solutions," Powalisz noted. The Patent Pending status provides the company with a 12-month window to advance research, partnerships, and commercialization pathways while maintaining strategic confidentiality.
Company Operations and Expansion
Adia Nutrition Inc. (搜索), based in Winter Park, Florida, operates through multiple divisions including Adia Med (搜索) clinics specializing in orthopedic care, pain management, and wound repair. The company's lab division, Adia Labs LLC, focuses on stem cell and regenerative products such as AdiaVita (搜索) and AdiaLink (搜索), with expansion plans to include insurance-billable wound care products.
Revenue generation occurs through service fees, product sales, equity stakes, and insurance billing for healthcare treatments. The company actively seeks strategic partnerships with clinic owners and healthcare practitioners interested in licensing the Adia Med (搜索) name or integrating regenerative therapies into their practice.